CANcer TOxicities. Cohort of women with localized breast cancer: study of the chronic toxicities of cancer treatments 


The CANTO study aims to describe the chronic toxicities of cancer treatments, to identify the populations likely to develop them and to adapt the treatments accordingly, in order to guarantee a better quality of life.

Key elements

  • Since 2012
  • 13,250 women with stage I to III breast cancer

Objectives of the cohorte

For ten years, the CANTO study has supported more than 13,000 women treated for breast cancer.

The project has four specific objectives:

  • Listing the adverse events occurring in these women and potentially linked to the chronic toxicity of cancer treatments (surgery, radiation therapy, hormone therapy, etc.).
  • Describing the chronic toxicity of such treatments (incidence, clinical and biological picture, etc.).
  • Describing the psychosocial and economic impact of chronic toxicities.
  • Developing predictive models of chronic toxicity, based on the study of genetic polymorphisms (SNP arrays, genetic variants) and serum biomarkers (proteins, antibodies).

Its purpose is to improve the quality of life of women treated for localized breast cancer by preventing the toxic effects of treatment. It is part of one of the pillars of the Cancer Plan 2: life after cancer.

Recent publications

I Vaz Luis et al., UNICANCER- French prospective cohort study of treatment-related chronic toxicity in women with localized breast cancer (CANTO), ESMO Open, 2019

Di Meglio et al., Body weight and return to work among survivors of early-stage breast cancer, ESMO Open, 2020

S. Lee et al., Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association Data, JNCI cancer spectrum, 2020

A Dumas et al., Impact of Breast Cancer Treatment and its Physical and Psychological Late Effects on Employment – Results of a Multicenter Prospective Cohort Study (CANTO), Journal of Clinical Oncology, 2020

B Pistilli et al., Serum detection of non-adherence to adjuvant tamoxifen and breast cancer recurrence risk, Journal of Clinical Oncology, 2020

  • Plus de publications ici.                                                                      

Management and governance

The CANTO study is coordinated by Dr Fabrice André, oncologist at the Gustave Roussy Cancer Institute (IGR, Villejuif) and research director at the National Institute of Health and Medical Research (Inserm), in Inserm unit U981 - Gustave Roussy Institute – Paris-Sud 11 University “Predictive biomarkers and new molecular strategies in cancer therapy”.

Terms and conditions of accessing cohort data

  • Project leaders wishing to use the database and/or the sample collection can contact the team in charge of the cohort at UNICANCER via the address
  • A standard descriptive sheet must be filled out by the project leader, in order to be able to distribute it to the executive committee of the CANTO study.
  • If the project is accepted, then the sponsor is informed and a data/sample transfer contract is drawn up.
  • The database collecting the study information is hosted by Unicancer (HDS host). 

Detailed information